Lilly 
 
4Q Revenues: $6.0 billion (-1%)

4Q Earnings: $827.2 million (-4%)

YTD Revenues: $22.6 billion (-7%) 

YTD Earnings: $4.1 billion (-6%)

Comments: Revenue in the U.S. was down 2% to $3.2 billion and revenue outside the U.S. was down 1% to $2.7 billion. Revenue decline included a 3% decrease due to lower volume, driven by the loss of patent exclusivity for Zyprexa in most major markets (-49% to $384.8 million), and 1% due to the unfavorable effect of foreign exchange rates. Humulin sales were down 1% in the quarter to $343.0 million, driven primarily by lower demand. Cymbalta sales were up 20% in the quarter to $1.4 billion. Alimta sales were up 7% to $684.3 million. Cialis sales were $513.4 million (+4%). Forteo sales were $314.6 million (+20%). Effient sales were up 33% to $120.6 million.